Alvotech Swiss AG

Quick facts

Marketed products

• Simponi · Oncology

Phase 3 pipeline

• Adalimumab biosimilar · Immunology
  Adalimumab biosimilar is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.
• Adalimumab originator · Immunology
  Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
• AVT03 · Immunology / Rheumatology
  AVT03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
• AVT04 · Oncology
  AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• Eylea® (Aflibercept) · Ophthalmology
  Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.
• Eylea HD (aflibercept HD) · Ophthalmology
  Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.
• Simponi (Golimumab) · Immunology
  Simponi (Golimumab) is a monoclonal antibody that selectively binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.

Phase 1 pipeline

• AVT05
• AVT32-DRL_PB
• AVT80
• Geographical region 1 Entyvio
• Geographical region 2 Entyvio
• Stelara PFS

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Alvotech Swiss AG portfolio CI brief
• Alvotech Swiss AG pipeline updates RSS